Sustained inhibition of intimal thickening. In vitro and in vivo effects of polymeric beta-cyclodextrin sulfate.
Intimal thickening after vascular injury may be modulated in part by heparin binding growth factors. We hypothesized that placement of a therapeutic polymer in the periadventitial space capable of tightly binding growth factors might alter the vascular response to injury. We first demonstrated that incubation of rat aortic smooth muscle cells with an insoluble, sulfated polymer of beta-cyclodextrin (P-CDS) was associated with a dose-dependent inhibition of proliferation induced by fetal calf serum, fibroblast growth factor-2 (FGF-2), platelet-derived growth factor BB, or epidermal growth factor. Preincubation studies of P-CDS with FGF-2 revealed a very rapid removal of mitogenic activity. Using radiolabeled FGF-2 (0.25 microg/ml), we observed a very rapid association rate (0.34 +/- 0.07 min-1, n=4) and a very slow dissociation rate (3.3 +/- 0.2 X 10(-7) min-1) at 37 degrees C, suggesting a high affinity interaction. Using both Transwell and linear under-agarose assays, we demonstrated a significant inhibition of random migration (chemokinesis) by P-CDS. Unsulfated polymeric beta-cyclodextrin (P-CD) had little if any of these effects, suggesting that the high negative charge density of P-CDS was important for the effects. Finally, rats undergoing carotid artery balloon injury were randomized to treatment with periadventitial P-CDS or no treatment, and were killed at 4 (n=20), 14 (n=59), and 88 d (n=14). Morphometric analysis demonstrated significant and sustained inhibition of intimal thickening in P-CDS-treated rats at 14 (P < 0.01) and 88 d (P < 0.05) using absolute intimal area or intima/media area ratios. No inhibition was seen in a group of rats treated with P-CD. In P-CDS-treated rats, bromodeoxyuridine labeling studies revealed fewer labeled smooth muscle cells in the intima at 14 d (P=0.01), while staining with Evans blue revealed enhanced late endothelial cell regrowth. Thus, periadventitially applied sulfated beta-cyclodextrin polymer, which can tightly bind heparin binding growth factors, inhibits intimal thickening in vivo in a sustained fashion without using an additional delivery system. These studies suggest that cellular processes mediated by heparin binding growth factors may be modulated by P-CDS.
Bachinsky
W B
WB
University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
Barnathan
E S
ES
Liu
H
H
Okada
S S
SS
Kuo
A
A
Raghunath
P N
PN
Muttreja
M
M
Caron
R J
RJ
Tomaszewski
J E
JE
Golden
M A
MA
D000800:Angioplasty, Balloon; D000818:Animals; D001011:Aorta / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D000077214:Becaplermin; D002339:Carotid Arteries / Q000187:drug effects* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003505:Cyclodextrins / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D006133:Growth Substances / Q000494:pharmacology*; D007700:Kinetics; D009924:Organ Culture Techniques; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011108:Polymers / Q000633:toxicity; D020574:Proto-Oncogene Proteins c-sis; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology; D013936:Thymidine / Q000378:metabolism; D017539:Tunica Intima / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D047392:beta-Cyclodextrins
D003505:Cyclodextrins; D006133:Growth Substances; D010982:Platelet-Derived Growth Factor; D011108:Polymers; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D047392:beta-Cyclodextrins; D016222:Fibroblast Growth Factor 2; C064089:beta-cyclodextrin tetradecasulfate; D000077214:Becaplermin; D004815:Epidermal Growth Factor; D013936:Thymidine